

Attorney Docket No. 6594.200-US
 Sauerberg et al.
 Serial No. 10/734,368 Filed December 12, 2003
 Via Facsimile No.: 571-273-8300


RECEIVED
 CENTRAL FAX CENTER

SEP 06 2007

AMENDMENTS TO THE CLAIMS

CLAIM LISTING

1. (Currently amended) A compound of ~~the general~~ formula (I):



wherein A is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;
 - R₄ represents aryl optionally substituted with one or more halogens; or

A is -O-A' or -S-A' wherein -O- or -S- is linked to X in formula (I) and wherein A' is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;

Attorney Docket No. 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

- o R₄ represents aryl optionally substituted with one or more halogens; and

B is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - o R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;
 - o R₄ represents aryl optionally substituted with one or more halogens; or

B is -O-B' or -S-B' wherein -O- or -S- is linked to Y in formula (I) and wherein B' is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - o R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;
 - o R₄ represents aryl optionally substituted with one or more halogens; and

D is H, C₁₋₆-alkyl or C₃₋₆-cycloalkyl; and

E is H, C₁₋₆-alkyl or C₃₋₆-cycloalkyl; and

L and M are independently -O- or -S-; and

Attorney Docket No. 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

T is C₁₋₆ divalent saturated carbon chain optionally substituted with one or more substituents selected from

- halogen or hydroxy; or
- aryl, aralkoxy or C₁₋₃-alkoxy which is optionally substituted with halogen; or

T is -NR₁-T' wherein -NR₁- is linked to Z in formula (I) and wherein T' is C₁₋₆ alkylene which is optionally substituted with one or more halogen and R₁ represents hydrogen or C₁₋₃ alkyl; and

U is C₁₋₆ divalent saturated carbon chain optionally substituted with one or more substituents selected from

- halogen or hydroxy; or
- aryl, aralkoxy or C₁₋₃-alkoxy which is optionally substituted with halogen; or

U is -NR₁-U' wherein -NR₁- is linked to Z in formula (I) and wherein U' is C₁₋₆ alkylene which is optionally substituted with one or more halogen and R₁ represents hydrogen or C₁₋₃ alkyl; and

X is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from

- halogen or hydroxy; or
- C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio, aryl, aralkyl each of which is optionally substituted with one or more halogens; or

Y is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from

- halogen or hydroxy; or
- C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio, aryl, aralkyl each of which is optionally substituted with one or more halogens; or

Attorney Docket No. 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

Z is ~~arylene, heteroarylene or~~ a divalent polycyclic ringsystem ~~each of which is~~ optionally substituted with one or more substituents selected from

- halogen, oxo or hydroxy; or
- C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio each of which is optionally substituted with one or more halogen; or

a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers, racemic mixture, or polymorphs.

2. (Original) A compound according to claim 1 wherein A is C₁₋₃-alkylene, which is optionally substituted with one or more substituents selected from

- methyl, C₁₋₃-alkoxy, C₃₋₆-cycloalkoxy or benzyloxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen and R₂ represents -R₃-(C=O)-R₄ wherein:
 - o R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or phenylene optionally substituted with one or more halogens;
 - o R₄ represents phenyl optionally substituted with one or more halogens.

3. (Original) A compound according to claim 2 wherein A is methylene or ethylene each of which is optionally substituted with one or more substituents selected from

- methoxy or ethoxy; or
- NR₁R₂ wherein R₁ represents hydrogen and R₂ represents -R₃-(C=O)-R₄ wherein R₃ and R₄ represents phenyl.

4. (Original) A compound according to claim 2 wherein A is ethylene which is optionally substituted with ethoxy.

Attorney Docket No 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

5. (Withdrawn) A compound according to claim 1 wherein A is -O-A' or -S-A' wherein -O- or -S- is linked to X in formula (I) and wherein A' is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy or aralkoxy each of which is optionally substituted with halogen.

6. (Withdrawn) A compound according to claim 5 wherein A is -O-A' or -S-A' wherein -O- or -S- is linked to X in formula (I) and wherein A' is methylene or ethylene each of which is optionally substituted with one or more substituents selected from methyl, methoxy or ethoxy.

7. (Withdrawn) A compound according to claim 6 wherein A is -O-A' wherein -O- is linked to X in formula (I) and wherein A' is methylene or ethylene.

8. (Withdrawn) A compound according to claim 7 wherein A is -O-A' wherein -O- is linked to X in formula (I) and wherein A' is methylene.

9. (Original) A compound according to claim 1 wherein B is C₁₋₃-alkylene, which is optionally substituted with one or more substituents selected from

- methyl, C₁₋₃-alkoxy, C₃₋₆-cycloalkoxy or benzyloxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen and R₂ represents -R₃-(C=O)-R₄ wherein:
 - R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or phenylene optionally substituted with one or more halogens;
 - R₄ represents phenyl optionally substituted with one or more halogens.

10. (Original) A compound according to claim 9 wherein B is methylene or ethylene each of which is optionally substituted with one or more substituents selected from

- methoxy or ethoxy; or

Attorney Docket No 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

- NR_1R_2 wherein R_1 represents hydrogen and R_2 represents $-\text{R}_3-(\text{C}=\text{O})-\text{R}_4$ wherein R_3 and R_4 represents phenyl.
11. (Original) A compound according to claim 9 wherein B is ethylene which is optionally substituted with ethoxy.
12. (Withdrawn) A compound according to claim 1 wherein B is $-\text{O}-\text{B}'$ or $-\text{S}-\text{B}'$ wherein $-\text{O}-$ or $-\text{S}-$ is linked to Y in formula (I) and wherein B' is C_{1-3} -alkylene which is optionally substituted with one or more substituents selected from
- halogen or
 - C_{1-3} -alkyl, C_{1-6} -alkoxy, C_{3-6} -cycloalkoxy or aralkoxy each of which is optionally substituted with halogen.
13. (Withdrawn) A compound according to claim 12 wherein B is $-\text{O}-\text{B}'$ or $-\text{S}-\text{B}'$ wherein $-\text{O}-$ or $-\text{S}-$ is linked to Y in formula (I) and wherein B' is methylene or ethylene each of which is optionally substituted with one or more substituents selected from methyl, methoxy or ethoxy.
14. (Withdrawn) A compound according to claim 13 wherein B is $-\text{O}-\text{B}'$ wherein $-\text{O}-$ is linked to Y in formula (I) and wherein B' is methylene or ethylene.
15. (Withdrawn) A compound according to claim 14 wherein B is $-\text{O}-\text{B}'$ wherein $-\text{O}-$ is linked to Y in formula (I) and wherein B' is methylene.
16. (Original) A compound according to claim 1 wherein D is H.
17. (Original) A compound according to claim 1 wherein D is methyl or ethyl.
18. (Original) A compound according to claim 1 wherein D is isopropyl.
19. (Original) A compound according to claim 1 wherein E is H.

Attorney Docket No 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

20. (Original) A compound according to claim 1 wherein E is methyl or ethyl.
21. (Original) A compound according to claim 1 wherein E is isopropyl.
22. (Original) A compound according to claim 1 wherein L is -O-.
23. (Withdrawn) A compound according to claim 1 wherein L is -S-.
24. (Original) A compound according to claim 1 wherein M is -O-.
25. (Withdrawn) A compound according to claim 1 wherein M is -S-.
26. (Original) A compound according to claim 1 wherein T is C₁₋₆ divalent saturated carbon chain optionally substituted with one or more substituents selected from phenyl, benzyloxy or C₁₋₃-alkoxy which is optionally substituted with halogen.
27. (Original) A compound according to claim 26 wherein T is an unsubstituted C₁₋₆ divalent saturated carbon chain.
28. (Original) A compound according to claim 27 wherein T is ethylene or propylene.
29. (Withdrawn) A compound according to claim 1 wherein T is -NR₁-T' wherein -NR₁- is linked to Z in formula (I) and wherein T' is C₁₋₆ alkylene which is optionally substituted with one or more halogen and R₁ represents hydrogen or C₁₋₃ alkyl.
30. (Withdrawn) A compound according to claim 29 wherein T is -NR₁-T' wherein -NR₁- is linked to Z in formula (I) and wherein T' is C₁₋₃ alkylene and R₁ represents hydrogen or C₁₋₃ alkyl.
31. (Withdrawn) A compound according to claim 30 wherein T is -NR₁-T' wherein -NR₁- is linked to Z in formula (I) and wherein T' is ethylene and R₁ is methyl.

Attorney Docket No. 6594.200-US
Saucerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

32. (Original) A compound according to claim 1 wherein U is C₁₋₆ divalent saturated carbon chain optionally substituted with one or more substituents selected from phenyl, benzyloxy or C₁₋₃-alkoxy which is optionally substituted with halogen.
33. (Original) A compound according to claim 32 wherein U is an unsubstituted C₁₋₆ divalent saturated carbon chain.
34. (Original) A compound according to claim 33 wherein U is ethylene or propylene.
35. (Withdrawn) A compound according to claim 1 wherein U is -NR₁-U' wherein -NR₁- is linked to Z in formula (I) and wherein U' is C₁₋₆ alkylene which is optionally substituted with one or more halogen and R₁ represents hydrogen or C₁₋₃ alkyl.
36. (Withdrawn) A compound according to claim 35 wherein U is -NR₁-U' wherein -NR₁- is linked to Z in formula (I) and wherein U' is C₁₋₃ alkylene and R₁ represents hydrogen or C₁₋₃ alkyl.
37. (Withdrawn) A compound according to claim 36 wherein U is -NR₁-U' wherein -NR₁- is linked to Z in formula (I) and wherein U' is ethylene and R₁ is methyl.
38. (Original) A compound according to claim 1 wherein X is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from
- halogen; or
 - C₁₋₆-alkyl, C₁₋₆-alkoxy, aryl each of which is optionally substituted with one or more halogen.
39. (Original) A compound according to claim 38 wherein X is arylene optionally substituted with one or more substituents selected from
- halogen; or
 - C₁₋₆-alkyl, C₁₋₆-alkoxy, aryl each of which is optionally substituted with one or more halogen.

Attorney Docket No. 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

40. (Original) A compound according to claim 39 wherein X is phenylene optionally substituted with one or more substituents selected from
- halogen; or
 - C₁₋₃-alkyl, C₁₋₃-alkoxy, phenyl each of which is optionally substituted with one or more halogen.
41. (Original) A compound according to claim 40 wherein X is phenylene optionally substituted with one or more halogen, methyl or phenyl.
42. (Original) A compound according to claim 40 wherein X is phenylene optionally substituted with one or more trifluoromethyl or methoxy.
43. (Original) A compound according to claim 1 wherein Y is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from
- halogen; or
 - C₁₋₆-alkyl, C₁₋₆-alkoxy, aryl each of which is optionally substituted with one or more halogen.
44. (Original) A compound according to claim 43 wherein Y is arylene optionally substituted with one or more substituents selected from
- halogen; or
 - C₁₋₆-alkyl, C₁₋₆-alkoxy, aryl each of which is optionally substituted with one or more halogen.
45. (Original) A compound according to claim 44 wherein Y is phenylene optionally substituted with one or more substituents selected from
- halogen; or
 - C₁₋₃-alkyl, C₁₋₃-alkoxy, phenyl each of which is optionally substituted with one or more halogen.

Attorney Docket No 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

46. (Original) A compound according to claim 45 wherein Y is phenylene optionally substituted with one or more halogen, methyl or phenyl.

47. (Original) A compound according to claim 45 wherein Y is phenylene optionally substituted with one or more trifluoromethyl or methoxy.

48. (Currently amended) A compound according to claim 1 wherein Z is ~~arylene, heteroarylene or~~ a divalent polycyclic ringsystem ~~each of which is~~ optionally substituted with one or more substituents selected from

- halogen, oxo; or
- C₁₋₆-alkyl, C₁₋₆-alkoxy each of which is optionally substituted with one or more halogen.

49. Cancelled

50. Cancelled


51. Cancelled

52. Cancelled

53. (Withdrawn) A compound according to claim 52 wherein Z is:




54. (Currently amended) A compound according to claim ~~48~~ 52 wherein Z is:




which is optionally substituted with one or more of trifluoromethyl.

55. (Withdrawn) A compound according to claim 52 wherein Z is:




Attorney Docket No. 6594.200-US
 Sauerberg et al.
 Serial No. 10/734,368 Filed December 12, 2003
 Via Facsimile No.: 571-273-8300

56. (Withdrawn) A compound according to claim 51 wherein Z is:



57. (Withdrawn) A compound according to claim 51 wherein Z is:



58. (Currently amended) The compound according to claim 1 which is selected from the following group:

- 2-Ethoxy-3-[4-(2-[(6-[(2-[4-(2-ethoxy-2-methoxycarbonyl-ethyl)-phenylsulfanyl]-ethyl)-methyl-amino]-pyridin-2-yl]-methyl-amino)-ethylsulfanyl)-phenyl]-propionic acid;
- 3-[4-(2-[(6-[(2-[4-(2-Carboxy-2-ethoxy-ethyl)-2-chloro-phenylsulfanyl]-ethyl)-methyl-amino]-pyridin-2-yl]-methyl-amino)-ethylsulfanyl)-3-chloro-phenyl]-2-ethoxy-propionic acid;
- (5'-[2-[(6-[(2-(2'-Ethoxycarbonylmethoxy-[1,1';3',1'']terphenyl-5'-yloxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy)-[1,1';3',1'']terphenyl-2'-yloxy)-acetic acid;
- (5'-[2-[(6-[(2-(2'-Carboxymethoxy-[1,1';3',1'']terphenyl-5'-yloxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy)-[1,1';3',1'']terphenyl-2'-yloxy)-acetic acid;
- (S,S)-2-(2-Benzoyl-phenylamino)-3-[4-[2-[(6-[(2-[4-(2-(2-benzoyl-phenylamino)-2-methoxycarbonyl-ethyl)-phenoxy]-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl]-propionic acid;
- (S,S)-2-(2-Benzoyl-phenylamino)-3-[4-[2-[(6-[(2-[4-(2-(2-benzoyl-phenylamino)-2-carboxy-ethyl)-phenoxy]-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl]-propionic acid;
- (3-Chloro-4-[2-[(6-[(2-(2-chloro-4-ethoxycarbonylmethyl-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl)-acetic acid;
- (4-[2-[(6-[(2-[4-Carboxymethyl-2-chloro-phenoxy]-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-3-chloro-phenyl)-acetic acid;

Attorney Docket No 6594.200-US
 Sauerberg et al.
 Serial No. 10/734,368 Filed December 12, 2003
 Via Facsimile No.: 571-273-8300

~~(3-{2-[(6-{[2-(3-Ethoxycarbonylmethyl-phenoxy)-ethyl]-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethoxy)-phenyl}-acetic acid;~~
~~(3-{2-[(6-{[2-(3-Carboxymethyl-phenoxy)-ethyl]-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethoxy)-phenyl}-acetic acid;~~
~~(S,S)-2-Ethoxy-3-[4-{2-[(6-{[2-(4-(2-ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-ethyl)-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethoxy)-phenyl]-propionic acid;~~
~~(S,S)-3-[4-{2-[(6-{[2-(4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl)-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethoxy)-phenyl]-2-ethoxy-propionic acid;~~
 (S,S)-2-Ethoxy-3-{4-[3-(4'-(3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-propionic acid;
 (S,S)-3-{4-[3-(4'-(3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
 (S,S)-2-Ethoxy-3-{4-[3-(4'-(3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-propionic acid;
 (S,S)-3-{4-[3-(4'-(3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
 (S,S)-3-{3-Bromo-4-[3-(4'-(3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
 (S,S)-3-{3-Bromo-4-[3-(4'-(3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
 (S,S)-3-{3-Bromo-4-[3-(4'-(3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
 (S,S)-3-{3-Bromo-4-[3-(4'-(3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
 (S,S)-3-{3-Bromo-4-[3-(7-(3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-9H-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid isopropyl ester;
 (S,S)-3-{3-Bromo-4-[3-(7-(3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-9H-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
 (S,S)-2-Ethoxy-3-{4-[3-(7-(3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-9H-fluoren-2-yl)-propoxy]-phenyl}-propionic acid isopropyl ester;
 (S,S)-3-{4-[3-(7-(3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-9H-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

Attorney Docket No 6594.200-US
 Sauerberg et al.
 Serial No. 10/734,368 Filed December 12, 2003
 Via Facsimile No.: 571-273-8300

[4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
 [4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
 [4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
 [4-(3-{7-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-9H-fluoren-2-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
 [4-(3-{7-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-9H-fluoren-2-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
 (4-{2-[2-(3-{4-[2-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;
 (4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;
 (S,S)-2-Ethoxy-3-[4-(2-{2-[4'-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid;
 (S,S)-3-[4-(2-{2-[4'-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-2-ethoxy-propionic acid;
 (S,S)-2-Ethoxy-3-[4-(2-{2-[3-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid;
 and
 (S,S)-3-[4-(2-{2-[3-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-2-ethoxy-propionic acid; or
 a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

59. (Currently amended) The compound according to claim 1 which is selected from the following group:

~~2-Ethoxy-3-[4-(2-{[6-((2-[4-(2-ethoxy-2-methoxycarbonyl-ethyl)-phenylsulfanyl]-ethyl)-methyl-amino)-pyridin-2-yl]-methyl-amino)-ethylsulfanyl]-phenyl]-propionic acid-methyl-ester;~~

Attorney Docket No. 6594.200-US
 Saucberg et al.
 Serial No. 10/734,368 Filed December 12, 2003
 Via Facsimile No.: 571-273-8300

~~(5'-{2-[(6-[(2-(2-Ethoxycarbonylmethoxy-[1,1',3',1'']terphenyl-5'-yloxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy}-[1,1',3',1'']terphenyl-2'-yloxy)-acetic acid-ethyl ester;~~

~~(S,S)-2-(2-Benzoyl-phenylamino)-3-[4-[2-[(6-[(2-[4-[2-(2-benzoyl-phenylamino)-2-methoxycarbonyl-ethyl]-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl]-propionic acid methyl ester;~~

~~(3-Chloro-4-[2-[(6-[(2-(2-chloro-4-ethoxycarbonylmethyl-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl)-acetic acid-ethyl ester;~~

~~(3-[2-[(6-[(2-(2-Ethoxycarbonylmethyl-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl)-acetic acid-ethyl ester;~~

~~(S,S)-2-Ethoxy-3-[4-[2-[(6-[(2-[4-(2-ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl]-propionic acid-ethyl ester;~~

~~(S,S)-2-Ethoxy-3-[4-[3-(4'-[3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-propionic acid isopropyl ester;~~

~~(S,S)-2-Ethoxy-3-[4-[3-(4'-[3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-propionic acid isopropyl ester;~~

~~(S,S)-3-[3-Bromo-4-[3-(4'-[3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid isopropyl ester;~~

~~(S,S)-3-[3-Bromo-4-[3-(4'-[3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid isopropyl ester;~~

~~[4-(3-[4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-2-methyl-phenoxy]-acetic acid methyl ester;~~

~~[4-(3-[4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-2-methyl-phenoxy]-acetic acid;~~

~~[4-(3-[4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-2-methyl-phenoxy]-acetic acid methyl ester;~~

~~[4-(3-[7-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-9H-fluoren-2-yl)-propylsulfanyl]-2-methyl-phenoxy]-acetic acid methyl ester;~~

Attorney Docket No 6594.200-US
 Sauerberg et al.
 Serial No. 10/734,368 Filed December 12, 2003
 Via Facsimile No.: 571-273-8300

(4-{2-[2-(3-{4-[2-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl]-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid methyl ester;

(S,S)-2-Ethoxy-3-[4-(2-{2-[4'-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl)-5-methyl-oxazol-2-yl]-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid isopropyl ester; and

(S,S)-2-Ethoxy-3-[4-(2-{2-[3-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl)-5-methyl-oxazol-2-yl]-phenyl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid isopropyl ester; or

a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

60. (Withdrawn) The compound according to claim 1 which is selected from the following group:

[4-(3-{4'-[3-(4-Carboxymethylsulfanyl-3-chloro-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-chloro-phenylsulfanyl]-acetic acid;

[4-[3-[4'-[3-(4-Carboxymethoxy-3-trifluoromethylphenylsulfanyl)propyl]biphenyl-4-yl]-propylsulfanyl]-2-trifluoromethylphenoxy]acetic acid;

[4-[3-[4'-[3-(4-Carboxymethoxy-3-chlorophenylsulfanyl)propyl]-3,3'-bis-trifluoromethylbiphenyl-4-yl]propylsulfanyl]-2-chlorophenoxy]acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-chloro-phenylsulfanyl)-propyl]-biphenyl-4-yl}-propylsulfanyl)-2-chloro-phenoxy]-acetic acid; and

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methoxy-phenylsulfanyl)-propyl]-biphenyl-4-yl}-propylsulfanyl)-2-methoxy-phenoxy]-acetic acid; or

a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

61. (Currently amended) The compound according to claim 1 which is selected from the following group:

~~3-[4-(2-{[6-(2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl)-methyl-amino]-pyridin-2-yl}-methyl-amino)-ethoxy]-phenyl]-2-ethoxy-propionic acid;~~

Attorney Docket No. 6594.200-US
 Saucberg et al.
 Serial No. 10/734,368 Filed December 12, 2003
 Via Facsimile No.: 571-273-8300

~~(3-[2-[(6-[(2-(3-Carboxymethyl-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl)-acetic acid;~~
~~2-(2-Benzoyl-phenylamino)-3-[4-[2-[(6-[(2-[4-(2-benzoyl-phenylamino)-2-carboxy-ethyl]-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl]-propionic acid;~~
~~(5'-[2-[(6-[(2-(2'-Carboxymethoxy-[1,1';3',1'']terphenyl-5'-yloxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-[1,1';3',1'']terphenyl-2'-yloxy)-acetic acid;~~
~~3-[4-[2-[(6-[(2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenyl]-2-ethoxy-propionic acid;~~
~~(4-[2-[(6-[(2-(4-Carboxymethyl-2-chloro-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-3-chloro-phenyl)-acetic acid;~~
~~(4-[2-[(6-[(2-(4-Carboxymethyl-2-bromo-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-3-bromo-phenyl)-acetic acid;~~
~~(4-[2-[(6-[(2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-2-methyl-phenoxy)-acetic acid;~~
~~(4-[2-[(6-[(2-(4-Carboxymethoxy-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenoxy)-acetic acid;~~
~~(3-[2-[(6-[(2-(3-Carboxymethyl-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenyl)-acetic acid;~~
~~(4-[2-[(6-[(2-(4-Carboxymethyl-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenyl)-acetic acid;~~
~~2-(2-Benzoyl-phenylamino)-3-[4-[2-[(6-[(2-[4-(2-benzoyl-phenylamino)-2-carboxy-ethyl]-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenyl]-propionic acid;~~
~~3-[4-[2-[(6-[(2-[4-(2-Carboxy-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-ethyl)-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenyl]-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-propionic acid;~~
~~3-[4-[2-[(6-[(2-[4-(2-Carboxy-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-ethyl)-phenoxy)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl]-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-propionic acid;~~
~~(4-[2-[(6-[(2-(4-Carboxymethyl-2-chloro-phenylsulfanyl)-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-3-chloro-phenyl)-acetic acid;~~

Attorney Docket No 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

~~(4-{2-[(6-{[2-(4-Carboxymethyl-2-bromo-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-3-bromo-phenyl)-acetic acid;~~

3-[4-(2-{2-[3-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-2-ethoxy-propionic acid;

(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;

(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenoxy)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl]-ethoxy}-2-methyl-phenoxy)-acetic acid;

(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-phenoxy)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl]-ethoxy}-phenoxy)-acetic acid;

(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl]-ethylsulfanyl}-phenoxy)-acetic acid;

3-[4-(2-{2-[3-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenylsulfanyl]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl]-ethylsulfanyl)-phenyl]-2-ethoxy-propionic acid;

3-{4-[3-(7-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-9H-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

3-{4-[3-(7-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenylsulfanyl]-propyl}-9H-fluoren-2-yl)-propylsulfanyl]-phenyl}-2-ethoxy-propionic acid;

[4-(3-{7-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-9H-fluoren-2-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;

[4-(3-{7-[3-(4-Carboxymethoxy-phenylsulfanyl)-propyl]-9H-fluoren-2-yl}-propylsulfanyl)-phenoxy]-acetic acid;

3-{3-Bromo-4-[3-(7-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl]-9H-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

3-{3-Bromo-4-[3-(7-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenylsulfanyl]-propyl]-9H-fluoren-2-yl)-propylsulfanyl]-phenyl}-2-ethoxy-propionic acid;

3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

Attorney Docket No 6594.200-US
Sauerberg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-2-methyl-phenoxy]-acetic acid;
[4-(3-{4'-[3-(4-Carboxymethoxy-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-phenoxy]-acetic acid;
[4-(3-{4'-[3-(4-Carboxymethoxy-phenoxy)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenoxy]-acetic acid;
[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenoxy)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-2-methyl-phenoxy]-acetic acid;
[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-2-methyl-phenoxy]-acetic acid;
[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenoxy)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-2-methyl-phenoxy]-acetic acid; and
3-{4-(2-{4'-[4-(2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl}-2-ethoxy-propionic acid; or
a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

62. (Withdrawn) A compound which is {4-[3-(4-{4-[3-(4-Carboxymethoxy-3-trifluoromethyl-phenylsulfanyl)-propyl]-2-trifluoromethyl-phenylsulfanyl}-3-trifluoromethyl-phenyl)-propylsulfanyl]-2-trifluoromethyl-phenoxy}-acetic acid or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

63. (Original) A compound according to claim 1, which is a PPAR δ agonist.

64. (Original) A compound according to claim 63, which is a selective PPAR δ agonist.

Attorney Docket No 6594.200-US
Sauerburg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

65. (Original) A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

66. (Currently amended) A pharmaceutical composition according to claim 65 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, ~~preferably~~ from about 0.1 to about 500 mg, or of and especially preferred from about 0.5 mg to about 200 mg ~~per day~~ of compound.

67. Cancelled

68. Cancelled

69. (Currently amended) A pharmaceutical composition according to claim 65 formulated for oral, nasal, transdermal, pulmonal, or parenteral administration.

70. (Withdrawn) A method for the treatment of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutical composition comprising the same.

71. (Withdrawn) A method for the treatment of type I diabetes, type II diabetes, dyslipidemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) or hypercholesteremia, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or of a pharmaceutical composition comprising the same.

72. (Withdrawn) The method according to claim 70 wherein the effective amount of the compound is in the range of from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day.

Attorney Docket No. 6594.200-US
Saucrborg et al.
Serial No. 10/734,368 Filed December 12, 2003
Via Facsimile No.: 571-273-8300

73. **(Withdrawn)** The method according to claim 71 wherein the effective amount of the compound is in the range of from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day.